Updated International Society of Geriatric Oncology COVID-19 working group recommendations on COVID-19 vaccination among older adults with cancer

Soto‐Pérez‐de‐Celis, Enrique; Mislang, Anna Rachelle; Hernández-Favela, Celia Gabriela; Russo, Chiara; Colloca, G.; Williams, Grant R.; O’Hanlon, Shane; Cooper, Linda J.; O’Donovan, Anita; Audisio, Riccardo A.; Cheung, Kwok-Leung; Gironés-Sarrió, Regina; Stauder, Reinhard; Jaklitsch, Michael T.; Cairo, Clarito; Gil, Luiz Antonio; Alam, Mahmood; Sattar, Schroder; Kantilal, Kumud; Loh, Kah Poh; Lichtman, Stuart M.; Brain, Étienne; Wildiers, Hans; Kanesvaran, Ravindran; Battisti, Nicolò Matteo Luca

doi:10.1016/j.jgo.2022.07.005

Cited by 2 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One explanation might be that follicular helper T-cells (Tfh) are required for adequate antibody generation. Indeed, it has been recently demonstrated in mice and humans, that IL-10-producing Tfh are increased with age and impaired humoral responses (40). Additionally, the authors demonstrated that IL-6 is required for the generation of IL-10-producing Tfh, and senescent T-cells have been described to secrete proinflammatory cytokines (39).…”

Section: Discussionmentioning

confidence: 99%

The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age

et al. 2023

View full text Add to dashboard Cite

PurposeCancer patients are at risk of severe COVID-19 infection, and vaccination is recommended. Nevertheless, we observe a failure of COVID-19 vaccines in this vulnerable population. We hypothesize that senescent peripheral T-cells alter COVID-19 vaccine-induced immunity.MethodsWe performed a monocentric prospective study and enrolled cancer patients and healthy donors before the COVID-19 vaccination. The primary objective was to assess the association of peripheral senescent T-cells (CD28-CD57+KLRG1+) with COVID-19 vaccine-induced immunity.ResultsEighty cancer patients have been included, with serological and specific T-cell responses evaluated before and at 3 months post-vaccination. Age ≥ 70 years was the principal clinical factor negatively influencing the serological (p=0.035) and specific SARS-CoV-2 T-cell responses (p=0.047). The presence of senescent T-cells was correlated to lower serological (p=0.049) and specific T-cell responses (p=0.009). Our results sustained the definition of a specific cut-off for senescence immune phenotype (SIP) (≥ 5% of CD4 and ≥ 39.5% of CD8 T-cells), which was correlated to a lower serological response induced by COVID-19 vaccination for CD4 and CD8 SIPhigh (p=0.039 and p=0.049 respectively). While CD4 SIP level had no impact on COVID-19 vaccine efficacy in elderly patients, our results unraveled a possible predictive role for CD4 SIPhigh T-cell levels in younger cancer patients.ConclusionsElderly cancer patients have a poor serological response to vaccination; specific strategies are needed in this population. Also, the presence of a CD4 SIPhigh affects the serological response in younger patients and seems to be a potential biomarker of no vaccinal response.

show abstract

Section: Discussionmentioning

confidence: 99%

The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Desai et al [17] provided operational COVID-19 vaccine guidance for patients participating in oncology clinical trials, encouraging COVID-19 vaccination as standard of care for patients with cancer. As with general treatment guidelines, specific guidance for COVID vaccination among older adults with cancer is generally absent beyond the SIOG guidelines [6]. Thus, providers are providing guidance rather than institutions or larger entities.…”

Section: Discussionmentioning

confidence: 99%

“…In addition to COVID-19 risk, social restrictions, including distancing, isolation, and limited caregiver support, placed older adults with cancer in a more vulnerable position by potentially increasing their existing risk of frailty, functional decline, and mental health outcomes [3,4]. The International Society of Geriatric Oncology (SIOG) outlined opportunities aimed at adapting care of older adults with cancer in a rapidly evolving healthcare system and prioritizing them in the rollout of the COVID-19 vaccines to ensure continuity of evidence-based care for this population [5,6]. In addition to adverse patient impacts, healthcare providers have been experiencing a decline in their own physical and mental health, reporting increased stress and burnout and prematurely leaving the field, exacerbating an already existing healthcare provider shortage [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

Healthcare providers’ experiences of continuing care for older adults with cancer during the COVID-19 pandemic

et al. 2023

View full text Add to dashboard Cite

Purpose The COVID-19 pandemic has caused great strain on older adults with cancer and their healthcare providers. This study explored healthcare providers’ reported changes in cancer care, clinical barriers to care, patient questions, and the overall experiences of caring for older adults with cancer during the COVID-19 crisis. Methods The Advocacy Committee of the Cancer and Aging Research Group and the Association of Community Cancer Centers developed a survey for healthcare providers of adults with cancer, inquiring about their experiences during the pandemic. Responses from the survey’s four open-ended items were analyzed by four independent coders for identification of common themes using deductive and inductive methods. Results Participants ( n = 137) represented a variety of demographic and clinical experiences. Six overall themes emerged, including (1) telehealth use, (2) concerns for patient mental health, (3) patient physical and social isolation, (4) patient fear of contracting COVID-19, (5) continued disruptions to cancer care, and (6) patients seeking guidance, particularly regarding COVID-19 vaccination. Questions fielded by providers focused on the COVID-19 vaccination’s safety and efficacy during older adults’ cancer treatment. Conclusions Additional resources (e.g., technology support, established care guidelines, and sufficient staffing) are needed to support older adults with cancer and healthcare providers during the pandemic. Future research should explore universally effective in-person and virtual treatment strategies for older adults with cancer. Implications for Cancer Survivors Persistence of telehealth barriers, particularly a lack of infrastructure to support telehealth visits, social isolation, and restrictive visitor policies as a result of COVID-19, negatively impacted the mental health of older adults with cancer.

show abstract

Updated International Society of Geriatric Oncology COVID-19 working group recommendations on COVID-19 vaccination among older adults with cancer

Cited by 2 publications

References 25 publications

The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age

The presence of senescent peripheral T-cells is negatively correlated to COVID-19 vaccine-induced immunity in cancer patients under 70 years of age

Healthcare providers’ experiences of continuing care for older adults with cancer during the COVID-19 pandemic

Contact Info

Product

Resources

About